Logo image of FENC

FENNEC PHARMACEUTICALS INC (FENC) Stock Fundamental Analysis

NASDAQ:FENC - Nasdaq - CA31447P1009 - Common Stock - Currency: USD

6.28  -0.02 (-0.32%)

After market: 6.28 0 (0%)

Fundamental Rating

4

Overall FENC gets a fundamental rating of 4 out of 10. We evaluated FENC against 563 industry peers in the Biotechnology industry. While FENC seems to be doing ok healthwise, there are quite some concerns on its profitability. FENC has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year FENC has reported negative net income.
FENC had a positive operating cash flow in the past year.
In the past 5 years FENC always reported negative net income.
In the past 5 years FENC reported 4 times negative operating cash flow.
FENC Yearly Net Income VS EBIT VS OCF VS FCFFENC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

1.2 Ratios

With an excellent Return On Assets value of -0.97%, FENC belongs to the best of the industry, outperforming 90.05% of the companies in the same industry.
With an excellent Return On Invested Capital value of 5.33%, FENC belongs to the best of the industry, outperforming 93.78% of the companies in the same industry.
Industry RankSector Rank
ROA -0.97%
ROE N/A
ROIC 5.33%
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FENC Yearly ROA, ROE, ROICFENC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800

1.3 Margins

FENC's Operating Margin of 5.40% is amongst the best of the industry. FENC outperforms 93.25% of its industry peers.
FENC has a Gross Margin of 93.30%. This is amongst the best in the industry. FENC outperforms 93.43% of its industry peers.
Industry RankSector Rank
OM 5.4%
PM (TTM) N/A
GM 93.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FENC Yearly Profit, Operating, Gross MarginsFENC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for FENC has been increased compared to 1 year ago.
The number of shares outstanding for FENC has been increased compared to 5 years ago.
FENC has a better debt/assets ratio than last year.
FENC Yearly Shares OutstandingFENC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FENC Yearly Total Debt VS Total AssetsFENC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -2.55, we must say that FENC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of FENC (-2.55) is comparable to the rest of the industry.
The Debt to FCF ratio of FENC is 0.67, which is an excellent value as it means it would take FENC, only 0.67 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of FENC (0.67) is better than 95.56% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 0.67
Altman-Z -2.55
ROIC/WACCN/A
WACCN/A
FENC Yearly LT Debt VS Equity VS FCFFENC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

FENC has a Current Ratio of 6.38. This indicates that FENC is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of FENC (6.38) is better than 65.90% of its industry peers.
A Quick Ratio of 6.22 indicates that FENC has no problem at all paying its short term obligations.
FENC has a better Quick ratio (6.22) than 65.72% of its industry peers.
Industry RankSector Rank
Current Ratio 6.38
Quick Ratio 6.22
FENC Yearly Current Assets VS Current LiabilitesFENC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

FENC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 100.00%, which is quite impressive.
Looking at the last year, FENC shows a very strong growth in Revenue. The Revenue has grown by 123.55%.
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
Revenue 1Y (TTM)123.55%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-18.59%

3.2 Future

The Earnings Per Share is expected to grow by 229069.00% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 24.62% on average over the next years. This is a very strong growth
EPS Next Y122375411954613120%
EPS Next 2Y13663338241.47%
EPS Next 3Y32079500%
EPS Next 5Y229069%
Revenue Next Year-15.06%
Revenue Next 2Y20.74%
Revenue Next 3Y24.08%
Revenue Next 5Y24.62%

3.3 Evolution

FENC Yearly Revenue VS EstimatesFENC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
FENC Yearly EPS VS EstimatesFENC Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2 3

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

FENC is valuated quite expensively with a Price/Forward Earnings ratio of 92.45.
Compared to the rest of the industry, the Price/Forward Earnings ratio of FENC indicates a rather cheap valuation: FENC is cheaper than 90.59% of the companies listed in the same industry.
FENC's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 20.74.
Industry RankSector Rank
PE N/A
Fwd PE 92.45
FENC Price Earnings VS Forward Price EarningsFENC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, FENC is valued cheaper than 99.11% of the companies in the same industry.
Industry RankSector Rank
P/FCF 6.42
EV/EBITDA N/A
FENC Per share dataFENC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as FENC's earnings are expected to grow with 32079500.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13663338241.47%
EPS Next 3Y32079500%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FENC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FENNEC PHARMACEUTICALS INC

NASDAQ:FENC (5/5/2025, 8:08:43 PM)

After market: 6.28 0 (0%)

6.28

-0.02 (-0.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-10 2025-03-10/bmo
Earnings (Next)05-08 2025-05-08/bmo
Inst Owners58.82%
Inst Owner Change-0.06%
Ins Owners1.74%
Ins Owner Change0.25%
Market Cap173.33M
Analysts85.45
Price Target12.85 (104.62%)
Short Float %6.22%
Short Ratio16.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-132.1%
Min EPS beat(2)-135.44%
Max EPS beat(2)-128.76%
EPS beat(4)1
Avg EPS beat(4)-181.91%
Min EPS beat(4)-539.32%
Max EPS beat(4)75.87%
EPS beat(8)2
Avg EPS beat(8)-140.51%
EPS beat(12)4
Avg EPS beat(12)-101.83%
EPS beat(16)6
Avg EPS beat(16)-84.49%
Revenue beat(2)0
Avg Revenue beat(2)-38.7%
Min Revenue beat(2)-53.52%
Max Revenue beat(2)-23.88%
Revenue beat(4)1
Avg Revenue beat(4)-20.29%
Min Revenue beat(4)-53.52%
Max Revenue beat(4)31.8%
Revenue beat(8)3
Avg Revenue beat(8)-10.15%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-7.35%
EPS NQ rev (1m)0%
EPS NQ rev (3m)22.78%
EPS NY rev (1m)0%
EPS NY rev (3m)-60.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-20.39%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 92.45
P/S 3.65
P/FCF 6.42
P/OCF 6.42
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0
EYN/A
EPS(NY)0.07
Fwd EY1.08%
FCF(TTM)0.98
FCFY15.57%
OCF(TTM)0.98
OCFY15.57%
SpS1.72
BVpS-0.21
TBVpS-0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.97%
ROE N/A
ROCE 6.75%
ROIC 5.33%
ROICexc 17.81%
ROICexgc 17.81%
OM 5.4%
PM (TTM) N/A
GM 93.3%
FCFM 56.75%
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover1.06
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 0.67
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.38
Quick Ratio 6.22
Altman-Z -2.55
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
EPS Next Y122375411954613120%
EPS Next 2Y13663338241.47%
EPS Next 3Y32079500%
EPS Next 5Y229069%
Revenue 1Y (TTM)123.55%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-18.59%
Revenue Next Year-15.06%
Revenue Next 2Y20.74%
Revenue Next 3Y24.08%
Revenue Next 5Y24.62%
EBIT growth 1Y120.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1912.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y257.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y257.38%
OCF growth 3YN/A
OCF growth 5YN/A